
Geron (GERN) Stock Forecast & Price Target
Geron (GERN) Analyst Ratings
Bulls say
Geron Corp’s stock outlook appears positive due to the European Commission's recent approval of Rytelo (imetelstat) for treating low-risk myelodysplastic syndrome (LR-MDS), which is anticipated to significantly enhance revenue streams starting in 2026. The company's strategic plans to educate healthcare providers about Rytelo, coupled with the strong prescriber feedback indicating its effectiveness, are expected to drive sales growth in both first-line and second-line treatment settings. Furthermore, potential approval for relapsed/refractory myelofibrosis could further double the commercial opportunity for Rytelo, solidifying Geron's position in the oncology market.
Bears say
Geron Corp's recent financial performance indicates a concerning trend, with management reporting flat revenue growth due to a slowdown in the Rytelo launch for lower-risk myelodysplastic syndromes. The company's reliance on 3rd-line patients for the majority of Rytelo prescriptions, coupled with disappointing uptake among 2nd-line patients, suggests challenges in expanding market penetration. Additionally, lowered peak sales expectations for Rytelo, now projected at $1.0 billion compared to previous estimates of $1.2 billion, highlight the increasing risks associated with the company’s clinical programs and competitive pressures in the oncology market.
This aggregate rating is based on analysts' research of Geron and is not a guaranteed prediction by Public.com or investment advice.
Geron (GERN) Analyst Forecast & Price Prediction
Start investing in Geron (GERN)
Order type
Buy in
Order amount
Est. shares
0 shares